

Francesco Grossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1634903/publications.pdf>

Version: 2024-02-01

370
papers

15,139
citations

53939

47
h-index

27587

110
g-index

385
all docs

385
docs citations

385
times ranked

18617
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	13.9	4,701
2	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
3	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , 2021, 397, 375-386.	6.3	638
4	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , 2020, 21, 914-922.	5.1	503
5	Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1835-1842.	0.8	421
6	Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1443-1448.	0.8	276
7	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 479-485.	1.2	253
8	Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 546.	1.7	177
9	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 713-721.	5.1	157
10	IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2009, 125, 887-893.	2.3	151
11	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	3.2	139
12	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
13	PD-1/PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1242.	2.2	130
14	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1281-1287.	0.8	126
15	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
16	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	0.9	122
17	Pleural and Peripheral Lung Lesions: Comparison of US- and CT-guided Biopsy. <i>Radiology</i> , 2013, 266, 930-935.	3.6	115
18	Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1463-1472.	2.0	110

#	ARTICLE	IF	CITATIONS
19	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008, 99, 51-56.	2.9	107
20	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	1.8	103
21	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
22	Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2006, 107, 2842-2849.	2.0	98
23	Exosomes: a new horizon in lung cancer. <i>Drug Discovery Today</i> , 2017, 22, 927-936.	3.2	90
24	Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013, 109, 552-558.	2.9	89
25	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134.	1.3	83
26	Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). <i>Oncologist</i> , 2007, 12, 1215-1224.	1.9	82
27	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. <i>Cancers</i> , 2020, 12, 17.	1.7	82
28	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
29	Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. <i>European Journal of Cancer</i> , 2020, 132, 17-23.	1.3	79
30	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	0.5	77
31	Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. <i>European Journal of Cancer</i> , 2003, 39, 1242-1250.	1.3	76
32	Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2008, 13, 14-20.	1.9	73
33	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
34	ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. <i>British Journal of Cancer</i> , 2013, 108, 1695-1703.	2.9	67
35	Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature. <i>Oncologist</i> , 2007, 12, 451-464.	1.9	65
36	Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. <i>Oncologist</i> , 2009, 14, 497-510.	1.9	64

#	ARTICLE	IF	CITATIONS
37	Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens. <i>Oncologist</i> , 2010, 15, 1102-1112.	1.9	64
38	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. <i>Frontiers in Oncology</i> , 2014, 4, 242.	1.3	63
39	The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2003, 39, 353-357.	1.3	62
40	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
41	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
42	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 799-811.	5.1	56
43	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4774.	1.8	55
44	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 123, 72-80.	1.3	54
45	The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 61-67.	2.0	53
46	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 125.	2.2	53
47	In Vitro Study of CI-994, a Histone Deacetylase Inhibitor, in Non-Small Cell Lung Cancer Cell Lines. <i>Oncology Research</i> , 2005, 15, 39-48.	0.6	52
48	Messinian Lago-Mare deposits near the Strait of Gibraltar (Malaga Basin, S Spain). <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2010, 285, 264-276.	1.0	51
49	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50
50	Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 4417-4420.	3.3	49
51	Geography of clinical cancer research publications from 1995 to 1999. <i>European Journal of Cancer</i> , 2003, 39, 106-111.	1.3	49
52	A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2013, 24, 2382-2389.	0.6	49
53	Paratethyan Ostracod immigrants in Italy during the Late Miocene. <i>Geobios</i> , 2007, 40, 325-337.	0.7	48
54	Understanding the checkpoint blockade in lung cancer immunotherapy. <i>Drug Discovery Today</i> , 2017, 22, 1266-1273.	3.2	48

#	ARTICLE	IF	CITATIONS
55	Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 233-240.	0.8	47
56	Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1260-1266.	0.5	46
57	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013, 49, 2815-2822.	1.3	45
58	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
59	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 1438-1447.	5.1	45
60	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: ¹⁸ F-FDG PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1764-1769.	2.8	44
61	Comparison Between ¹⁸ F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 990-998.	2.8	44
62	IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions. <i>PLoS ONE</i> , 2009, 4, e6119.	1.1	43
63	Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. <i>Clinical Lung Cancer</i> , 2011, 12, 407-411.	1.1	43
64	Ramucirumab: preclinical research and clinical development. <i>OncoTargets and Therapy</i> , 2014, 7, 1997.	1.0	43
65	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1035.	1.8	39
66	Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. <i>Journal of Clinical Oncology</i> , 2019, 37, 2201-2205.	0.8	39
67	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. <i>Current Drug Targets</i> , 2015, 16, 47-59.	1.0	38
68	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. <i>Cancers</i> , 2021, 13, 1794.	1.7	38
69	Outpatient Hysteroscopic Polypectomy in 237 Patients: Feasibility of a One-Stop "See-and-Treat" Procedure. <i>Journal of Minimally Invasive Gynecology</i> , 2004, 11, 500-504.	1.4	37
70	Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. <i>International Journal of Cancer</i> , 2008, 123, 1108-1116.	2.3	37
71	Orbitally forced paleoenvironmental and paleoclimate changes in the late postevaporitic Messinian of the central Mediterranean Basin. <i>Bulletin of the Geological Society of America</i> , 2012, 124, 499-516.	1.6	35
72	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM, Φ Platform. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28765-28782.	1.8	35

#	ARTICLE	IF	CITATIONS
73	Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. <i>Clinical Lung Cancer</i> , 2019, 20, 178-185.e2.	1.1	35
74	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	1.9	35
75	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \geq 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	2.0	35
76	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 3542-3561.	1.4	35
77	Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?. <i>European Journal of Cancer</i> , 2006, 42, 8-16.	1.3	34
78	Easternmost Mediterranean evidence of the Zanclean flooding event and subsequent surface uplift: Adana Basin, southern Turkey. <i>Geological Society Special Publication</i> , 2013, 372, 473-494.	0.8	34
79	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. <i>Targeted Oncology</i> , 2015, 10, 393-404.	1.7	34
80	Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 183-196.	2.0	33
81	Late Messinian lago-mare ostracod palaeoecology: A correspondence analysis approach. <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2008, 264, 288-295.	1.0	33
82	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. <i>Drug Discovery Today</i> , 2014, 19, 1671-1676.	3.2	33
83	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	0.5	33
84	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021, 13, 653.	2.0	33
85	Management of Malignant Pleural Effusions. <i>Drugs</i> , 1998, 55, 47-58.	4.9	31
86	Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. <i>Molecular Cancer</i> , 2013, 12, 97.	7.9	31
87	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2865-2878.	2.4	31
88	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	0.8	30
89	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. <i>Lung Cancer</i> , 2011, 74, 529-534.	0.9	29
90	Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1704-1708.	0.5	29

#	ARTICLE	IF	CITATIONS
91	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103059.	2.0	29
92	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 733-737.	0.5	28
93	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 665-672.	0.5	28
94	Is <i>Cyprideis agrigentina</i> Decima a good paleosalinometer for the Messinian Salinity Crisis? Morphometrical and geochemical analyses from the Eraclea Minoa section (Sicily). <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2015, 419, 75-89.	1.0	27
95	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. <i>BMC Cancer</i> , 2016, 16, 692.	1.1	27
96	Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. <i>Medicinal Research Reviews</i> , 2018, 38, 1447-1468.	5.0	27
97	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2055-2062.	0.9	27
98	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. <i>Cancer Management and Research</i> , 2020, Volume 12, 675-686.	0.9	27
99	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 68627-68640.	0.8	27
100	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. <i>Lung Cancer</i> , 2010, 69, S11-S17.	0.9	26
101	Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer. <i>Disease Markers</i> , 2015, 2015, 1-18.	0.6	26
102	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
103	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. <i>Cancers</i> , 2020, 12, 3310.	1.7	25
104	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.	1.8	25
105	Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. <i>BMC Cancer</i> , 2008, 8, 216.	1.1	24
106	Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014). <i>Journal of Thoracic Oncology</i> , 2010, 5, 1354-1360.	0.5	24
107	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α -mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3320-3334.	1.4	24
108	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1545-1558.	0.9	24

#	ARTICLE	IF	CITATIONS
109	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1969-1976.	0.9	24
110	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	2.0	24
111	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
112	Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 1999, 81, 310-315.	2.9	23
113	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	1.1	23
114	DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 224-229.	0.9	23
115	Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e183486.	3.4	23
116	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 998.	1.7	23
117	Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. <i>Lung Cancer</i> , 2001, 33, 27-39.	0.9	22
118	Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study. <i>Journal of Thoracic Oncology</i> , 2007, 2, 475-480.	0.5	22
119	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1585-1599.	0.9	22
120	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. <i>Molecular Medicine</i> , 2019, 25, 15.	1.9	22
121	Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. <i>Journal of Thoracic Disease</i> , 2020, 12, 3390-3398.	0.6	22
122	Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 6518-6526.	3.2	21
123	Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 31.	0.7	21
124	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 889-903.	0.9	21
125	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
126	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 513-523.	1.9	21

#	ARTICLE	IF	CITATIONS
127	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
128	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2628.	1.8	21
129	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib's LUX-Lung 5 (LL5). <i>Journal of Clinical Oncology</i> , 2014, 32, 8019-8019.	0.8	21
130	Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 132, 101-106.	0.5	20
131	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. <i>Lung Cancer</i> , 2009, 64, 199-206.	0.9	20
132	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013, 81, 236-240.	0.9	20
133	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. <i>Cancers</i> , 2019, 11, 1095.	1.7	20
134	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020, 12, 2452.	1.7	20
135	«Earliest Zanclean age for the Colombacci and uppermost Di Tetto formations of the «latest Messinian» northern Apennines: New palaeoenvironmental data from the Maccarone section (Marche) Tj ETQq1d.784314 rgBT /		
136	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 939-948.	1.4	19
137	A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 465-471.	0.9	19
138	NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 1133-e112.	1.9	19
139	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
140	Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group. <i>Acta Oncologica</i> , 2006, 45, 168-174.	0.8	18
141	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage III-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). <i>British Journal of Cancer</i> , 2012, 106, 658-665.	2.9	18
142	Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. <i>British Journal of Cancer</i> , 2017, 116, 36-43.	2.9	18
143	Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. <i>Anticancer Research</i> , 2008, 28, 507-13.	0.5	18
144	The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 1999, 10, S13-S17.	0.6	17

#	ARTICLE	IF	CITATIONS
145	Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 221-230.	2.0	17
146	Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 16-26.	2.0	17
147	CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 829-835.	1.4	17
148	Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. <i>European Journal of Cancer</i> , 2020, 135, 47-50.	1.3	17
149	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)., 2021, 9, e002619.		17
150	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021, 13, 3117.	1.7	17
151	Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?. <i>World Journal of Radiology</i> , 2017, 9, 27.	0.5	17
152	Maintenance chemotherapy in non-small cell lung cancer. <i>Annals of Oncology</i> , 2006, 17, ii67-ii70.	0.6	16
153	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. <i>Future Oncology</i> , 2014, 10, 2081-2096.	1.1	16
154	Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. <i>Annals of Oncology</i> , 2016, 27, vi425.	0.6	16
155	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. <i>International Journal of Epidemiology</i> , 2018, 47, 1981-1991.	0.9	16
156	Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study. <i>Annals of Oncology</i> , 2000, 11, 1413-1420.	0.6	15
157	CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 207-214.	1.0	15
158	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2016, 5, 12-18.	0.6	15
159	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 449-456.	1.7	15
160	Advances in treatment of mesothelioma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1197-1205.	0.9	14
161	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020, 12, 2948.	1.7	14
162	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	1.4	14

#	ARTICLE	IF	CITATIONS
163	Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. <i>Clinical Therapeutics</i> , 2020, 42, 830-847.	1.1	14
164	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	1.8	14
165	Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 804-808.	2.4	13
166	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7720-7727.	1.4	13
167	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 117, 64-69.	0.9	13
168	Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1427-1435.	1.0	13
169	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 101-110.	0.6	13
170	Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study. <i>Cancer Research</i> , 2019, 79, CT043-CT043.	0.4	13
171	Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). <i>Lung Cancer</i> , 2006, 52, 89-92.	0.9	12
172	Belagenpumatucel-L for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1371-1379.	1.4	12
173	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. <i>Medicine (United States)</i> , 2016, 95, e5447.	0.4	12
174	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. <i>Immunotherapy</i> , 2019, 11, 873-879.	1.0	12
175	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , 2019, 134, 210-217.	0.9	12
176	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. <i>Biomedicines</i> , 2021, 9, 607.	1.4	12
177	5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. <i>British Journal of Cancer</i> , 2001, 84, 1023-1028.	2.9	11
178	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). <i>Lung Cancer</i> , 2004, 46, 99-106.	0.9	11
179	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e50-e52.	0.5	11
180	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2015, 137, 2947-2958.	2.3	11

#	ARTICLE	IF	CITATIONS
181	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 125.	1.7	11
182	Facies analysis in the Second Cycle Messinian evaporites predating the early Pliocene reflooding: the Balza Soletta section (Corvillo Basin, central Sicily). <i>Italian Journal of Geosciences</i> , 2019, 138, 301-316.	0.4	11
183	Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. <i>ESMO Open</i> , 2021, 6, 100051.	2.0	11
184	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	2.0	11
185	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1007-1017.	1.4	10
186	30 Immunotherapy in advanced NSCLCâ€”from the â€˜tsunamiâ€™™ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	2.0	10
187	New insight into the Pleistocene deposits of Monte delle Piche, Rome, and remarks on the biochronology of <i>Hippopotamus</i> (Mammalia, Hippopotamidae) and <i>Stephanorhinus etruscus</i> (Mammalia, Rhinocerotidae) in Italy. <i>Estudios Geologicos</i> , 2015, 71, e026.	0.7	10
188	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1407-1412.	1.1	9
189	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. <i>Current Clinical Pharmacology</i> , 2018, 13, 76-84.	0.2	9
190	LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. <i>Annals of Oncology</i> , 2020, 31, S1441.	0.6	9
191	Triage process for the assessment of coronavirus disease 2019â€”positive patients with cancer: The ONCOVID prospective study. <i>Cancer</i> , 2021, 127, 1091-1101.	2.0	9
192	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	0.9	9
193	Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective. <i>European Journal of Cancer</i> , 2004, 40, 1850-1854.	1.3	8
194	Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule. <i>Pharmacoeconomics Italian Research Articles</i> , 2007, 9, 113-124.	0.2	8
195	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1783-1793.	1.2	8
196	P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S493.	0.5	8
197	The record of the Messinian salinity crisis in mobile belts: Insights from the Molise allochthonous units (southern Apennines, Italy). <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2018, 503, 112-130.	1.0	8
198	PCSK9 is a promising prognostic marker in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 491-492.	2.0	8

#	ARTICLE	IF	CITATIONS
199	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021, 13, 1324.	1.7	8
200	Severe hypocalcemia and life-threatening ventricular arrhythmias: case report and proposal of a diagnostic and therapeutic algorithm. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015, 12, 265-8.	1.0	8
201	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1142-1154.	0.9	8
202	Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 147.	1.8	8
203	Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. <i>Cytotechnology</i> , 1996, 19, 215-219.	0.7	7
204	Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.. <i>International Journal of Oncology</i> , 1999, 15, 787-92.	1.4	7
205	Management of Italian Patients With Advanced Non-Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. <i>Clinical Lung Cancer</i> , 2014, 15, 338-345.e1.	1.1	7
206	Hematopoietic growth factors in lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 135-144.	1.1	7
207	Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4300-4304.	0.6	7
208	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 931-940.	0.9	7
209	Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial. <i>Lancet Oncology</i> , 2021, 22, 573-575.	5.1	7
210	Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. <i>European Journal of Cancer</i> , 2021, 148, 112-116.	1.3	7
211	A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM). <i>Journal of Clinical Oncology</i> , 2005, 23, 7172-7172.	0.8	7
212	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20522-e20522.	0.8	7
213	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
214	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An AlpeAdria Thoracic Oncology Multidisciplinary group trial (ATOM) Tj ETQq0 0 0 rgB3 /Overlock 10 Tf 50		
215	Management of Non-Small Cell Lung in Cancer Patients with Stable Disease. <i>Drugs</i> , 2012, 72, 20-27.	4.9	6
216	Is the occurrence of a sigmoidal ventral border in <i>Cyprideis torosa</i> (Jones) valves linked to salinity? A morphometrical analysis approach. <i>Journal of Micropalaeontology</i> , 2017, 36, 70-79.	1.3	6

#	ARTICLE	IF	CITATIONS
217	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 19-33.	0.9	6
218	Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 705-705.	0.7	6
219	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6
220	COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report. <i>Melanoma Research</i> , 2021, 31, 490-493.	0.6	6
221	Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. <i>Cancer Research</i> , 2018, 78, CT075-CT075.	0.4	6
222	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/ gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7558-7558.	0.8	6
223	Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7501-7501.	0.8	6
224	Mobile Emergency, an Emergency Support System for Hospitals in Mobile Devices: Pilot Study. <i>JMIR Research Protocols</i> , 2013, 2, e19.	0.5	6
225	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, 1055.	1.6	6
226	Bevacizumab and non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1107-1119.	1.4	5
227	Dynamic behaviour of lactate values during mild hypothermia in patients with cardiac arrest. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 176-182.	0.4	5
228	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1-4.	1.1	5
229	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 551-561.	1.9	5
230	Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000270.	0.2	5
231	Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy. <i>Annals of Oncology</i> , 2017, 28, v469.	0.6	5
232	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , 2019, 14, e0224027.	1.1	5
233	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	5
234	Immune related adverse events and response to immunotherapy: Focus on corticosteroids. <i>Lung Cancer</i> , 2020, 145, 225.	0.9	5

#	ARTICLE	IF	CITATIONS
235	Serum levels of VCAM α 1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	1.7	5
236	PCSK9 as a new player in cancer: New opportunity or red herring?. <i>Current Medicinal Chemistry</i> , 2021, 28, .	1.2	5
237	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
238	Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer. <i>Anticancer Research</i> , 2002, 22, 3519-24.	0.5	5
239	Penetration of Cefonicid into Serum, Salpinges, Cervix and Vaginal Tissue. <i>Journal of Chemotherapy</i> , 1991, 3, 28-29.	0.7	4
240	New perspectives for the pharmacological and biological therapy of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 31, 135-145.	2.0	4
241	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5353-5356.	1.0	4
242	Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries. <i>Current Medical Research and Opinion</i> , 2016, 32, 1577-1584.	0.9	4
243	MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Thoracic Oncology</i> , 2018, 13, S390-S391.	0.5	4
244	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019, 134, 121-126.	0.9	4
245	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 705-713.	1.1	4
246	Managing patients with lung cancer. <i>BMJ: British Medical Journal</i> , 2000, 320, 379-379.	2.4	4
247	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3067-3067.	0.8	4
248	To Treat or Not to Treat Advanced Non α Small-Cell Lung Cancer Patients With Impaired Performance Status?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7231-7232.	0.8	3
249	PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS. <i>Value in Health</i> , 2007, 10, A333.	0.1	3
250	A peer-education based disaster medicine course to turn medical students into a useful resource. <i>International Journal of Disaster Risk Reduction</i> , 2014, 8, 153-157.	1.8	3
251	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016, 100, 30-37.	0.9	3
252	Vinflunine for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1447-1455.	1.9	3

#	ARTICLE	IF	CITATIONS
253	P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S827-S828.	0.5	3
254	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. <i>Cancers</i> , 2019, 11, 441.	1.7	3
255	PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189. <i>Journal of Thoracic Oncology</i> , 2019, 14, S1170-S1171.	0.5	3
256	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1603-1610.	1.2	3
257	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. <i>Viruses</i> , 2021, 13, 508.	1.5	3
258	Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2010, 28, 7581-7581.	0.8	3
259	Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized phase II trial (ATOM 017).. <i>Journal of Clinical Oncology</i> , 2010, 28, e18028-e18028.	0.8	3
260	Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib. <i>Clinical Pharmacology: Advances and Applications</i> , 2022, Volume 14, 1-9.	0.8	3
261	191 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2006, 54, S46.	0.9	2
262	B2-07: Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach. <i>Journal of Thoracic Oncology</i> , 2007, 2, S339.	0.5	2
263	9112 POSTER AVAPERL1 (MO22089) " Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). <i>European Journal of Cancer</i> , 2011, 47, S626.	1.3	2
264	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 369-375.	1.1	2
265	Valutazione economica in base allo studio NAVOTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. <i>Pharmacoeconomics Italian Research Article</i> , 2014, 16, 1.	0.2	2
266	Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy. <i>Annals of Oncology</i> , 2016, 27, vi369.	0.6	2
267	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1336-S1337.	0.5	2
268	MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1841.	0.5	2
269	Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression. <i>Annals of Oncology</i> , 2017, 28, vi61.	0.6	2
270	Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients. <i>Annals of Oncology</i> , 2017, 28, v410-v411.	0.6	2

#	ARTICLE	IF	CITATIONS
271	KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. <i>Annals of Oncology</i> , 2018, 29, viii529-viii530.	0.6	2
272	P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial). <i>Journal of Thoracic Oncology</i> , 2019, 14, S829-S830.	0.5	2
273	LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDia-2 study (Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal) <i>TJ ETQq1 1 0784314 rgBT /Over</i>	0.7	2
274	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 21, 218-230.e6.	1.1	2
275	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020, 31, S1078.	0.6	2
276	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, S825-S826.	0.6	2
277	1765P Developing a risk assessment score for cancer patients during the COVID-19 pandemic. <i>Annals of Oncology</i> , 2020, 31, S1026.	0.6	2
278	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVOTrial 03). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110229.	1.4	2
279	A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday. <i>Melanoma Research</i> , 2021, 31, 190-193.	0.6	2
280	Title is missing!. <i>Annals of Oncology</i> , 1999, 10, 13-17.	0.6	2
281	Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2007, 25, 18138-18138.	0.8	2
282	Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator arms. <i>Journal of Clinical Oncology</i> , 2008, 26, 8087-8087.	0.8	2
283	Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 7077-7077.	0.8	2
284	Evaluation of CTL antigen 4 (CTLA-4) expression as prognostic factor in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011, 29, e21157-e21157.	0.8	2
285	Potential of crizotinib activity by fasting cycles in an ALK+ lung cancer model.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13511-e13511.	0.8	2
286	Surgical resection of superior pulmonary sulcus tumor after neoadjuvant chemoradiation via the anterior transmanubrial approach: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 1603-1603.	0.7	2
287	Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 8077-8077.	0.8	2
288	Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. <i>International Journal of Oncology</i> , 1997, 11, 1203-8.	1.4	1

#	ARTICLE	IF	CITATIONS
289	Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. <i>British Journal of Cancer</i> , 2004, 91, 1428-1433.	2.9	1
290	Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 13-16.	0.3	1
291	9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naïve Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results. <i>European Journal of Cancer</i> , 2011, 47, S596.	1.3	1
292	Ribonucleotide reductase subunit 2 (RRM2) predicts shorter survival in resected stage III non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2012, 77, S23.	0.9	1
293	3123 Correlation between circulating tumor biomarkers and positronemission tomography in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, S644.	1.3	1
294	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1357-1364.	0.5	1
295	Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients. <i>Annals of Oncology</i> , 2017, 28, v470-v471.	0.6	1
296	MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1847.	0.5	1
297	Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy". <i>International Journal of Molecular Sciences</i> , 2017, 18, 1309.	1.8	1
298	Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification. <i>Journal of Thoracic Disease</i> , 2018, 10, E779-E783.	0.6	1
299	P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2018, 13, S481.	0.5	1
300	Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung. <i>Annals of Oncology</i> , 2019, 30, v646.	0.6	1
301	The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, v656.	0.6	1
302	Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts. <i>European Journal of Cancer</i> , 2020, 140, 161-162.	1.3	1
303	COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma. <i>Vaccines</i> , 2021, 9, 632.	2.1	1
304	Fatigue: A main component of anemia symptomatology. <i>Seminars in Oncology</i> , 2001, 28, 15-18.	0.8	1
305	Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemo-naïve patients (pts): Preliminary results of the phase I and pharmacokinetic study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7266-7266.	0.8	1
306	Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 007). <i>Journal of Clinical Oncology</i> , 2004, 22, 7363-7363.	0.8	1

#	ARTICLE	IF	CITATIONS
307	MicroRNA prognostic signature in malignant pleural mesothelioma.. Journal of Clinical Oncology, 2015, 33, 7562-7562.	0.8	1
308	PD-051 Final results of lung cancer and mesothelioma baselinescreening with low-dose spiral computed tomography (LDCT) in 1000 asbestos-exposed workers: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 002). Lung Cancer, 2005, 49, S81.	0.9	0
309	P-584 Single agent gemcitabine (GEM) in performance status (PS) 2-3 patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial. Lung Cancer, 2005, 49, S272.	0.9	0
310	P-961 Buccal mucosa cells as an in vivo model to evaluate gefitinib response in NSCLC patients. Lung Cancer, 2005, 49, S372-S373.	0.9	0
311	P-764 Phase II study of topotecan plus gemcitabine in previously treated small cell lung cancer (SCLC) patients: An Alpe-Adria Thoracic Oncology Multidisciplinary Group study (ATOM 012). Lung Cancer, 2005, 49, S320.	0.9	0
312	O2 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma (MPM). Critical Reviews in Oncology/Hematology, 2006, 60, S18.	2.0	0
313	6612 POSTER Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G). European Journal of Cancer, Supplement, 2007, 5, 392.	2.2	0
314	125PD FINAL REPORT OF A RANDOMIZED PHASE II STUDY OF DOCETAXEL/OXALIPLATIN (DO) AND DOCETAXEL (D) IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS). AN ALPE-ADRIA THORACIC ONCOLOGY MULTIDISCIPLINARY GROUP STUDY (ATOM 019). Lung Cancer, 2009, 64, S53.	0.9	0
315	9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC. European Journal of Cancer, 2011, 47, S593-S594.	1.3	0
316	Corrigendum to "Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy" [Lung Cancer 69S1 (2010) S11-S18]. Lung Cancer, 2011, 71, 118.	0.9	0
317	9147 POSTER Treatment and Clinical Outcomes of Young Patients (<40 Years) With Advanced Non-small Cell Lung (NSCLC) - Data From a Retrospective Multicentric Database. European Journal of Cancer, 2011, 47, S637-S638.	1.3	0
318	1446 POSTER Evaluation of CTL Antigen 4 (CTLA-4) Expression as Prognostic Factor in Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer, 2011, 47, S183.	1.3	0
319	The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line. Lung Cancer, 2012, 77, S30-S31.	0.9	0
320	Ribonucleotide Reductase Subunit 2 (RRM2) Predicts Shorter Survival in Resected Stage I-III Non-Small Cell Lung Cancer (NSCLC) Patients. Annals of Oncology, 2012, 23, ix79.	0.6	0
321	Front-Line Chemotherapy with or without NGR-HTNF in Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology, 2012, 23, ix410.	0.6	0
322	Afatinib in advanced non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 493-504.	1.5	0
323	A Novel Prognostic Microrna Signature in Malignant Pleural Mesothelioma. Annals of Oncology, 2014, 25, iv542.	0.6	0
324	Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1771-1780.	0.9	0

#	ARTICLE	IF	CITATIONS
325	Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?. Current Medical Research and Opinion, 2014, 30, 2291-2293.	0.9	0
326	Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non-Squamous non-Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries. Value in Health, 2015, 18, A446.	0.1	0
327	3047 Oral vinorelbine (NVBo) and cisplatin (P) as first-line chemotherapy (CT) in Asian and Caucasian non small cell lung cancer (NSCLC) patients (pts): Meta-analysis of 3 randomised studies. European Journal of Cancer, 2015, 51, S612.	1.3	0
328	3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM). European Journal of Cancer, 2015, 51, S634.	1.3	0
329	Clinical applications of a next-generation sequencing panel in non-small cell lung cancer. Annals of Oncology, 2015, 26, vi87.	0.6	0
330	P3.02c-092 Nivolumab in Multi-Treated Patients with Advanced Sq-NSCLC: Data from the Italian Cohort of Expanded Access Programme (EAP). Journal of Thoracic Oncology, 2017, 12, S1334-S1335.	0.5	0
331	MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response. Journal of Thoracic Oncology, 2017, 12, S401-S402.	0.5	0
332	MA 01.07 Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial. Journal of Thoracic Oncology, 2017, 12, S1801.	0.5	0
333	P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. Journal of Thoracic Oncology, 2017, 12, S1898.	0.5	0
334	The standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists. Annals of Oncology, 2018, 29, viii492.	0.6	0
335	Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. Annals of Oncology, 2018, 29, viii506-viii507.	0.6	0
336	Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type. Annals of Oncology, 2018, 29, viii520-viii521.	0.6	0
337	P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S531.	0.5	0
338	P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S730-S731.	0.5	0
339	P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience. Journal of Thoracic Oncology, 2018, 13, S490-S491.	0.5	0
340	P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer. Journal of Thoracic Oncology, 2018, 13, S726-S727.	0.5	0
341	Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing. Annals of Oncology, 2018, 29, viii674.	0.6	0
342	Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial. Annals of Oncology, 2019, 30, v645-v646.	0.6	0

#	ARTICLE	IF	CITATIONS
343	PC05.02 Are ICIs Effective for Poor Performance Status Patients with Advanced NSCLC?. Journal of Thoracic Oncology, 2019, 14, S145-S146.	0.5	0
344	P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patientsâ€™ Stratification and Identification of Responders to Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S458.	0.5	0
345	P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S742-S743.	0.5	0
346	1318P Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy. Annals of Oncology, 2020, 31, S851.	0.6	0
347	1689P The appropriateness of invasive ventilation in COVID-19 positive cancer patients: The hardest decision for oncologists. Annals of Oncology, 2020, 31, S998-S999.	0.6	0
348	1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study. Annals of Oncology, 2020, 31, S1001.	0.6	0
349	1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19). Annals of Oncology, 2020, 31, S1004-S1005.	0.6	0
350	Cancer Mechanisms and Emerging Therapies. Pharmaceuticals, 2021, 13, 1045.	2.0	0
351	Lung cancer and mesothelioma screening with low-dose spiral computed tomography (LDCT) in 1,000 asbestos-exposed workers: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM) Tj ETQq1 1 0.784314 rgBb/Overlo	0.8	0
352	Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis. Journal of Clinical Oncology, 2006, 24, 7138-7138.	0.8	0
353	Second line chemotherapy with topotecan and gemcitabine in small cell lung cancer (SCLC) patients: An Alpe-Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 012). Journal of Clinical Oncology, 2006, 24, 17014-17014.	0.8	0
354	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant subsets of stage IIIA N2 non-small cell lung cancer patients. An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 014). Journal of Clinical Oncology, 2006, 24, 10085-10085.	0.8	0
355	Randomized phase II trial of two sequential schedules of docetaxel (D) and cisplatin (C) followed by gemcitabine (G) in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology, 2007, 25, 18154-18154.	0.8	0
356	Final report of a randomized phase II study of docetaxel/oxaliplatin (DO) and docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). A novel design, Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 019). Journal of Clinical Oncology, 2009, 27, e19010-e19010.	0.8	0
357	Optimal duration of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC) in the first- and second-line settings. Journal of Clinical Oncology, 2009, 27, e19037-e19037.	0.8	0
358	Treatment and clinical outcome of young (age 40 and younger) patients with advanced non-small cell lung (NSCLC).. Journal of Clinical Oncology, 2010, 28, e18117-e18117.	0.8	0
359	ERCC1, BRCA1, thymidylate synthase (TS), class III beta tubulin (bTubIII), p53R2, RRM2 immunohistochemical expression in stage I-III non-small cell lung cancer (NSCLC): A tissue microarray (TMA) study.. Journal of Clinical Oncology, 2010, 28, e21094-e21094.	0.8	0
360	Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2010, 28, e18043-e18043.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results.. Journal of Clinical Oncology, 2011, 29, 7568-7568.	0.8	0
362	Abstract 5649: Investigational study of acquired resistance to the EGFR irreversible inhibitor afatinib (BIBW2992) in wild-type and EGFR-mutant NSCLC cell lines.. , 2013, , .		0
363	Serum mass-spectrometry test in first-line advanced NSCLC patients treated with standard chemotherapy regimens.. Journal of Clinical Oncology, 2014, 32, e19090-e19090.	0.8	0
364	The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT).. Journal of Clinical Oncology, 2015, 33, e19090-e19090.	0.8	0
365	Abstract 4008: MiRNA expression profiling reveals a prognostic signature in malignant pleural mesothelioma. , 2015, , .		0
366	Abstract 2521: In vitro and in vivo antitumor efficacy of sequentially combined vinorelbine and gefitinib in non-small cell lung cancer. , 2015, , .		0
367	Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.. Journal of Clinical Oncology, 2016, 34, 8513-8513.	0.8	0
368	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.. Journal of Clinical Oncology, 2016, 34, 1554-1554.	0.8	0
369	Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV <i>versus</i> gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type.. Journal of Clinical Oncology, 2018, 36, e21050-e21050.	0.8	0
370	Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial. Annals of Oncology, 2019, 30, ix172.	0.6	0